---
company: AMERICAN VANGUARD CORP
ticker: AVD
form: 8-K
filed: 2026-11-10
accepted: 2026-11-10T21:01:01+00:00
accession: 0001193125-26-455384
source: https://www.sec.gov/Archives/edgar/data/5981/000119312526455384/
---

# American Vanguard (AVD) Q3 2026 earnings

## Header

- Company: American Vanguard Corp
- Reported: 2026-11-10 16:01 AMC ET
- Source: 8-K only — accession 0001193125-26-455384, Item 2.02 + Exhibit 99.1
- Verdict: Adjusted EBITDA turned negative in Q3 despite revenue decline, driven by negative operating leverage and higher costs.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---:|---|---|
| Revenue | $108.4M | -9.0% | — | Ex. 99.1, income statement |
| EPS (GAAP) | -$0.61 | — | — | Ex. 99.1, income statement |
| Net income | -$17.7M | — | — | Ex. 99.1, income statement |
| Adj. EBITDA | -$24K | — | — | Ex. 99.1, income statement |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| U.S. Crop | $42.3M | -2.0% | 39% | Q3 only |
| U.S. Specialty | $18.9M | -2.0% | 17% | Q3 only |
| Total U.S. | $61.2M | -2.0% | 56% | Q3 only |
| International | $47.2M | -17.0% | 44% | Q3 only |
| Total net sales | $108.4M | -9.0% | 100% | Q3 only |

## Margins and costs

- Gross margin: 24.0% (prior 31%, change -7.0 pp)
- Operating expenses: -$32,826 (+3% YoY)
- One-offs in the quarter: CFO transition costs $1.3M; Product liability claims $22K; Asset impairments $0; Other $12K
- Effective tax rate: 3.2% (prior-year 3.5%, year-to-date 3.3%)
- Non-GAAP bridge: Adds back stock compensation, transformation costs, product liability claims, asset impairments, and other items; excludes amortization of intangibles from Adjusted operating expenses.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---|---|---:|
| Net trade working capital | $22M | — | — | +14% |
| Customer prepayments | $44.6M | — | — | +44% |
| Capital expenditures | $4.7M | — | — | — |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: Total sales fell 9% YoY to $108.4M; U.S. sales declined 2% while International sales dropped 17% YoY.
- EPS story: Net loss widened to -$0.61 per share from -$0.43 YoY, driven by lower revenue, higher costs, and negative operating leverage.
- One-off check: CFO transition costs of $1.3M and product liability claims of $22K are one-time items.

## The good

- U.S. market outperformance
- Customer prepayments up 44%
- Net trade working capital improved 14% YoY
- Adjusted operating expenses down 3% YoY

## The bad

- Adjusted EBITDA turned negative (-$24K)
- Gross margin compressed to 24%
- International sales down 17% YoY
- Operating loss widened to -$7.97M

## The ugly

- none

## Open questions

- How will the company recover gross margins given the sharp rise in diesel and transportation costs?
- What is the timeline for realizing the $4M annualized savings from the L.A. plant rationalization?

## Full release

### American Vanguard (AVD) earnings release, November 10, 2026

American Vanguard Corp (AVD) · Form 8-K, Item 2.02 · Filed 2026-11-10 · [SEC filing](https://www.sec.gov/Archives/edgar/data/5981/000119312526455384/)

American Vanguard Reports Third Quarter 2026 Results

Strategic Deals in Quarter Expand U.S. Product Portfolio

Consolidation Driving Manufacturing Efficiency Gains

El Nino and Geopolitics Pressure Global Agricultural Markets

Irvine, CA | November 9, 2026 — American Vanguard Corporation, a diversified specialty and agricultural products company that develops, manufactures, and markets solutions for crop protection and nutrition, turf and ornamental management and commercial pest control, today reported financial results for the third quarter and nine-months ended September 30, 2026.

Third Quarter 2026 Financial and Operational Highlights – versus Third Quarter 2025

Dak Kaye, CEO of American Vanguard, stated, “Our actions are taking hold, and the progress we are making across

American Vanguard continues to build, even as market conditions remain difficult, particularly outside the U.S., where El Niño is materially impacting our business this year. In the U.S., our largest and most important market, we continue to outperform our peers in a challenging environment. The cost actions we took in the first half, including the rationalization of our Los Angeles facility and the relocation of our headquarters are beginning to deliver operational savings. In the near term, however, those savings have been more than offset by a sharp rise in diesel and other transportation costs arising from instability in the Middle East. We are working to recover gross margins through commercial actions.”

Mr. Kaye continued, “Importantly, we are building a new product engine that we believe will drive growth over the next several years. At the end of the third quarter, we acquired four U.S. brands and registrations from Syngenta® and entered into a distribution agreement with Sipcam Agro, which together meaningfully expand our portfolio.

Combined with our pipeline of new product launches, these additions support our goal of driving $100 million in annualized revenue from new products by 2030. I am also pleased that we have further strengthened our leadership team in the quarter with the additions of Matt Horwath as Chief Financial Officer, and Hermann Castro, Senior Vice President of Marketing and Business Development, to drive new product development and Mark Helt as President of U.S. Crop. Our focus is the same in every market: stay close to our customers, provide service and solutions, and control what we can control.”¹

Matt Horwath, Chief Financial Officer, stated, “We began to see progress this quarter in terms of lower operating costs and improved manufacturing efficiencies as a result of actions taken earlier this year. However, this progress was more than offset in the quarter by the effects of negative operating leverage, driven by lower international sales and higher raw material and transportation costs. Net trade working capital improved by $22 million, or 14%, versus the prior year period. Higher pre-payments in the quarter, which increase by 44% year-over-year, demonstrate customer confidence and bode well for revenue in the 2027 planting season.”

Earnings Conference Call

The company will be hosting an earnings conference call on November 9, 2026 at 5:00 pm Eastern Time/2:00 pm Pacific Time.

The conference call will be webcast on the Company’s website at https://www.investors-american vanguard.com

/ or by going to the following link: https://www.webcaster5.com/Webcast/Page/3070/54771

If you are unable to listen live, the conference call will be archived for one year and may be accessed using the company’s website: https://www.investors-american-vanguard.com/

About American Vanguard

American Vanguard Corporation is a diversified specialty and agriculture products company that develops and markets products for crop protection and management, turf and ornamentals management, and public health. Over the past 20 years, through product and business acquisitions, the Company has significantly expanded its operations and now has more than 1,000 product registrations worldwide. To learn more about the Company, please reference www.american-vanguard.com.

The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release the matters set forth in this press release include forward-looking statements. These statements can be identified by the fact that they do not relate strictly to historical or current facts.

Forward looking statements often use words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “outlook,” “forecast,”

“target,” “trend,” “plan,” “goal,” or other words of comparable meaning or future-tense or conditional verbs such as “may,” “will,” “should,” “would,” or

“could.” These forward-looking statements are based on the current expectations and estimates by the Company’s management and are subject to various risks and uncertainties that may cause results to differ from management’s current expectations. Such factors include risks detailed from time-to-time in the Company’s SEC reports and filings. All forward-looking statements, if any, in this release represent the Company’s judgment as of the date of this release. The company disclaims any intent or obligation to update these forward-looking statements.²

Non-GAAP

Financial Measures

In addition to providing results that are determined in accordance with accounting principles generally accepted in the United States of America (GAAP), we present Adjusted EBITDA and Adjusted operating expenses, which are non-GAAP financial measures. These measures should not be considered in isolation or as an alternative to GAAP measures such as net income, or diluted earnings per share, as applicable, or other financial statement data presented in our financial statements as an indicator of our financial performance or liquidity.... (truncaITDA as net (loss) income, adjusted for depreciation and amortization, provision for income taxes and interest expense. We define Adjusted EBITDA as EBITDA as further adjusted for stock compensation expense and for certain items management believe are not reflective of the underlying operations of our business, including but not limited to the exclusion of charges that are considered by management to be unusual and not representative of the Company’s underlying performance and future prospects. In 2026 and 2025 that included non-recurring expenses. The resulting Adjusted EBITDA measure is aligned with the Company’s metric for its credit facility agreement in the applicable periods.

We define Adjusted operating expense as operating expenses as further adjusted for stock compensation expense and for certain items management believe are not reflective of the underlying operations of our business, including but not limited to the exclusion of charges that are considered by management to be unusual and not representative of the Company’s underlying performance and future prospects as well as the amortization expense for intangibles assets related to acquired product lines.

We use Adjusted EBITDA and Adjusted operating expenses to assess the operating results and effectiveness and efficiency of our business. We present this non-GAAP financial measure because we believe that investors consider Adjusted EBITDA and Adjusted operating expenses to be an important supplemental measure of performance, and we believe that this measure is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. As the Company continues to work through its transformation efforts, management believes that presenting Adjusted EBITDA and Adjusted operating expenses provides an effective comparison between the Company and its industry peers.

Non-GAAP financial measures as reported by us may not be comparable to similarly titled metrics reported by other companies and may not be calculated in the same manner. These measures have limitations as analytical tools, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP.

The Company is not able to provide a reconciliation without unreasonable efforts of its forward-looking guidance related to Adjusted EBITDA and Adjusted operating expenses to the most directly comparable GAAP financial measure due to the inherent difficulty in predicting with reasonable certainty the timing and amount of certain items that are excluded from Adjusted EBITDA and Adjusted operating expenses, such as share-based compensation, acquisition-related expenses, and foreign exchange gains or losses, which could be material to the Company’s results computed in accordance with GAAP.

Investor Representative

Alpha IR Group

Robert Winters

Robert.winters@alpha-ir.com

(917)

821-6305

#### Financial statements

##### Income Statement (For the Three Months Ended September 30, — (Unaudited) (in thousands))

| | For the Three Months Ended September 30, – 2026 | For the Three Months Ended September 30, – 2025 | For the Nine Months Ended September 30, – 2026 | For the Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Net sales | 108,376 | 119,313 | 348,698 | 364,426 |
| Cost of sales | -82,124 | -85,099 | -249,316 | -259,474 |
| Gross profit | 26,252 | 34,214 | 99,382 | 104,952 |
| **Operating expenses** | | | | |
| Selling, general and administrative | -25,797 | -26,747 | -80,133 | -81,998 |
| Research, product development and regulatory | -5,342 | -5,654 | -17,097 | -17,139 |
| Product liability claims | -22 | -7,029 | -223 | -7,029 |
| CFO transition costs | -1,316 |  | -1,316 |  |
| Transformation | -1,665 | -1,442 | -5,975 | -5,254 |
| Asset impairments |  | -93 | -943 | -227 |
| (Loss) gain from sale of assets | -75 | 246 | -75 | 246 |
| Operating loss | -7,965 | -6,505 | -6,380 | -6,449 |
| Change in fair value of an equity investment | -21 | -511 | -193 | -511 |
| Interest expense, net | -9,146 | -4,920 | -24,066 | -13,135 |
| Loss before provision for income taxes | -17,132 | -11,936 | -30,639 | -20,095 |
| Income tax expense | -536 | -422 | -1,043 | -1,574 |
| Net loss | -17,668 | -12,358 | -31,682 | -21,669 |
| Net loss per common share—basic | -0.61 | -0.43 | -1.1 | -0.76 |
| Net loss per common share—assuming dilution | -0.61 | -0.43 | -1.1 | -0.76 |
| Weighted average shares outstanding—basic | 28,775 | 28,511 | 28,691 | 28,377 |
| Weighted average shares outstanding—assuming dilution | 28,775 | 28,511 | 28,691 | 28,377 |

##### Income Statement (For the Three Months Ended September 30, — (Unaudited) (in thousands))

| | For the Three Months Ended September 30, – 2026 | For the Nine Months Ended September 30, – 2026 | For the Three Months Ended September 30, – 2025 | For the Nine Months Ended September 30, – 2025 | Change | % Change |
|---|---:|---:|---:|---:|---:|---:|
| **Net sales:** | | | | | | |
| U.S. Crop | 42,316 |  | 43,310 |  | -994 | -2.0% |
| U.S. Specialty | 18,872 |  | 19,233 |  | -361 | -2.0% |
| Total U.S. | 61,188 |  | 62,543 |  | -1,355 | -2.0% |
| International | 47,188 |  | 56,770 |  | -9,582 | -17.0% |
| Total net sales | 108,376 |  | 119,313 |  | -10,937 | -9.0% |
| Total cost of sales | -82,124 |  | -85,099 |  | 2,975 | -3.0% |
| Total gross profit | 26,252 |  | 34,214 |  | -7,962 | -23.0% |
| Total gross margin | 24.0% |  | 29 |  |  |  |
| U.S. Crop |  | 157,510 |  | 153,511 | 3,999 | 3.0% |
| U.S. Specialty |  | 57,045 |  | 54,067 | 2,978 | 6.0% |
| Total U.S. |  | 214,555 |  | 207,578 | 6,977 | 3.0% |
| International |  | 134,143 |  | 156,848 | -22,705 | -14.0% |
| Total net sales |  | 348,698 |  | 364,426 | -15,728 | -4.0% |
| Total cost of sales |  | -249,316 |  | -259,474 | 10,158 | -4.0% |
| Total gross profit |  | 99,382 |  | 104,952 | -5,570 | -5.0% |
| Total gross margin |  | 29.0% |  | 29 |  |  |

##### Income Statement (For the Three Months Ended September 30, — (Unaudited) (in thousands))

| | For the Three Months Ended September 30, – 2026 | For the Three Months Ended September 30, – 2025 | For the Nine Months Ended September 30, – 2026 | For the Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Net loss | -17,668 | -12,358 | -31,682 | -21,669 |
| Provision for income taxes | 536 | 422 | 1,043 | 1,574 |
| Interest expense, net | 9,146 | 4,920 | 24,066 | 13,135 |
| Depreciation and amortization | 4,620 | 4,565 | 13,861 | 14,023 |
| Stock compensation expense | 327 | 760 | 901 | 1,741 |
| CFO transition costs | 1,316 |  | 1,316 |  |
| Transformation costs | 1,665 | 1,442 | 5,975 | 5,254 |
| Product liability claims & related expenses | 22 | 7,610 | 223 | 7,610 |
| Asset impairments |  | 801 | 943 | 935 |
| Other | 12 | 48 | 203 | -381 |
| Adjusted EBITDA(1) | -24 | 8,210 | 16,849 | 22,222 |

##### Balance Sheet (September 30, 2026 — (In thousands, except share data) (Unaudited))

| | September 30, 2026 | December 31, 2025 |
|---|---:|---:|
| **Current assets:** | | |
| Cash | 83,909 | 12,425 |
| **Receivables:** | | |
| Trade, net of allowance for credit losses of $14,336 and $11,733, respectively | 142,677 | 160,511 |
| Other | 7,522 | 7,278 |
| Total receivables, net | 150,199 | 167,789 |
| Inventories | 194,079 | 176,034 |
| Prepaid expenses | 8,464 | 9,668 |
| Income taxes receivable | 1,750 | 4,606 |
| Total current assets | 438,401 | 370,522 |
| Property, plant and equipment, net | 51,956 | 53,036 |
| Operating lease right-of-use assets, net | 16,407 | 16,793 |
| Intangible assets, net | 139,809 | 138,746 |
| Deferred income tax assets | 2,963 | 2,637 |
| Other assets | 13,874 | 14,803 |
| Total assets | 663,410 | 596,537 |
| **Current liabilities:** | | |
| Accounts payable | 86,325 | 87,505 |
| Customer prepayments | 44,621 | 33,094 |
| Accrued program costs | 46,825 | 52,227 |
| Accrued expenses and other payables | 26,704 | 28,261 |
| Current portion of long-term debt | 3,750 |  |
| Operating lease liabilities, current | 5,637 | 5,765 |
| Income taxes payable | 3,370 | 2,594 |
| Total current liabilities | 217,232 | 209,446 |
| Long-term debt, net of current portion | 263,937 | 174,000 |
| Operating lease liabilities, long-term | 11,243 | 11,621 |
| Deferred income tax liabilities | 7,115 | 8,150 |
| Other liabilities | 760 | 923 |
| Total liabilities | 500,287 | 404,140 |

##### Cash Flow (For the Nine Months Ended September 30, — (Unaudited) (in thousands))

| | For the Nine Months Ended September 30, – 2026 | For the Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| **Cash flows from operating activities:** | | |
| Net loss | -31,682 | -21,669 |
| **Adjustments to reconcile net loss to net cash used in operating activities:** | | |
| Depreciation and amortization of property, plant and equipment and intangible assets | 13,442 | 14,007 |
| Amortization of other long-term assets | 5 | 16 |
| Loss (gain) on disposal of property, plant and equipment | 75 | -246 |
| Provision for estimated credit losses | 2,469 | 1,944 |
| Stock-based compensation | 901 | 1,741 |
| Deferred income taxes | -1,073 | -353 |
| Change in liabilities for uncertain tax positions or unrecognized tax benefits | -127 | -522 |
| Change in equity investment fair value | 193 | 511 |
| Impairment of assets | 943 | 227 |
| Payment-in-kind debt leverage fee | 1,261 |  |
| Amortization of deferred loan fees | 2,899 | 1,167 |
| Lease obligations and non-cash lease expense, net | -120 | -150 |
| Unrealized foreign currency transaction losses (gains) | 243 | -704 |
| **Changes in assets and liabilities associated with operations:** | | |
| Decrease in net receivables | 14,812 | 935 |
| Increase in inventories | -16,007 | -16,513 |
| Increase in prepaid expenses and other assets | -1,039 | -965 |
| Change in income tax receivable and payable, net | 3,526 | -1,083 |
| (Decrease) increase in accounts payable | -960 | 11,859 |
| Increase (decrease) in customer prepayments | 11,527 | -21,453 |
| (Decrease) increase in accrued program costs | -5,454 | 12,285 |
| Decrease in other payables and accrued expenses | -8,180 | -8,178 |
| Net cash used in operating activities | -12,346 | -27,144 |
| **Cash flows from investing activities:** | | |
| Capital expenditures | -4,676 | -2,398 |
| Proceeds from disposal of property, plant and equipment | 10 | 492 |
| Intangible assets | -5,149 | -136 |
| Net cash used in investing activities | -9,815 | -2,042 |
| **Cash flows from financing activities:** | | |
| Payments under line of credit agreement | -140,000 | -179,415 |
| Borrowings under line of credit agreement | 26,000 | 214,334 |
| Borrowings under term loans | 225,000 |  |
| Repayments of term loans | -1,125 |  |
| Payment of deferred loan fees | -16,581 | -3,339 |
| Net receipt from the issuance of common stock under ESPP | 474 | 629 |
| Net payment from common stock purchased for tax withholding | -99 | -147 |
| Net cash provided by financing activities | 93,669 | 32,062 |
| Net increase in cash | 71,508 | 2,876 |
| Effect of exchange rate changes on cash and cash equivalents | -24 | 1,405 |
| Cash at beginning of period | 12,425 | 12,514 |
| Cash at end of period | 83,909 | 16,795 |
